HCV

Tripled Hep C Rates Blamed on Opioid Crisis
Tripled Hep C Rates Blamed on Opioid CrisisThe surge in HCV transmission rates is being blamed on the opioid epidemic.
What's missing in hep C drugsPayers have unmet needs in the changing hepatitis C (HCV) space, according to a recent survey. The survey, from Precision for Value, highlights what can be done to encourage payers to ease coverage policies for these drugs in the next wave of HCV treatment.
Payers to pharma: Here’s what we’re missing in hep C drugsA Precision for Value survey highlights what can be done in order to encourage payers to ease coverage policies for these drugs in the next wave of HCV treatment.
Three ways to rein in drug costs regardless of who becomes presidentIt’s time for stakeholders to cooperate in order to limit the wasted spending on prescription medications and chart a path to collectively improving value derivation.
Four developments helping address the opioid epidemicAs the opioid epidemic continues across the U.S., new treatment programs and guidelines could help reverse the trend.
Cheaper hep C drug enters competitive market
Cheaper hep C drug enters competitive marketA new drug approved by FDA to treat chronic hepatitis C virus (HCV) infection this week enters a competitive, lucrative market headed up by Gilead Science’s Sovaldi and Harvoni, as well as AbbVie’s Viekira Pak. FDA granted priority review and breakthrough therapy designation to Gilead’s combination product, Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg).
Four critical components for successful, value-based pharma contractsDespite their proliferation, at-risk pharma contracts are still little more than value-based window dressing. Here are four critical components of contracts that can actually move the value meter in the right direction.
New diagnostic tests help physicians predict HCV drug resistanceHep C virus testing supports value of diagnostics in precision medicine.
'I love my job,' says UCSF expert in HIV/AIDS, HCVBetty J. Dong, clinician, researcher, professor, and recipient of many honors, talks about her practice of pharmacy and public health.
FDA expands use of hep C drugFDA has approved expanded use of daclatasvir (Daklinza, Bristol-Myers Squibb) in combination with Gilead Sciences' Sovaldi (sofosbuvir), for the treatment of patients with chronic hepatitis C (HCV) genotype 1 or 3.